In conclusion, our study demonstrates that MST1 can alleviate hepatic free cholesterol load and thus mitigate the progression of NASH through the regulation of AMPK/SREBP2 signaling. This evidence concerns the gene SREBF2 and metabolic dysfunction-associated steatohepatitis.